Evidence Review Team Jonathan C. Craig, MBChB, DipCH, FRACP, M Med (Clin Epi), PhD, Evidence Review Team Director, is an interna- tionally recognized clinician and scientist and holds the position of vice president and executive dean of the College of Medicine & Public Health at Flinders Univer- sity, Adelaide, South Australia. Professor Craig has made a signi cant contribution to the clinical research landscape in the prevention, identi cation, management, and treatment of CKD, particularly in relation to children and in indigenous communities. He has led the formation of state, national, and interna- tional networks to conduct high-quality, relevant trials in children. He has been instrumental in the development and implementation of best-practice methods and guidelines www.kidney-international.org biographic and disclosure information relating to CKD in Australia and globally. Professor Craig s many current advisory roles include member of the National Health and Medical Research Council s (NHMRC) Health Translation Advisory Committee, the Pharmaceutical Bene ts Advisory Committee, Medical Services Advisory Committee, and Commonwealth Department of Health Life Savings Drug Program. He is a past member of the World Health Organization expert review panel for global strategy and plan of action on public health, innovation and intellectual property; a past chairman of the Steering Group of the Cochrane Collaboration; and a past member of the Expert Advisory Group for the Structural Review of NHMRC s Grant Program. Dr. Craig declared no competing interests. Suetonia C. Palmer, MBChB, FRACP, PhD, Evidence Re- view Team Co-Director, is an academic nephrologist at the University of Otago at Christchurch in New Zealand. She studied medicine at the University of Otago, graduating in 1995. She became a fellow of the Royal Australasian Col- lege of Physicians in Nephrology in 2005. 